Aadi Bioscience Logo
US00032Q1040
A3CSR9
AADI

Aadi Bioscience

Forecast

The analysts' average price target is €1.49 (-46.79%). The median is €1.49 (-46.79%).

Buy
  3
Hold
  3
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, Aadi Bioscience had revenue of €0 and net profit of -€18.72m

(EUR) September 2026
YoY
Revenue 0 -
Gross profit 0 -
Net profit -18.72m 23.82%
EBITDA -20.26m 33.95%

Fundamentals

Metric Value
Market capitalization
€86.48m
Number of shares
46.29m
52-week high/low
€3.47 - €1.10
Dividends No
Beta
0.34
P/E ratio
-2.82
PEG ratio
0.00
P/B ratio
1.77
P/S ratio
0.00

Company profile

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Name
Aadi Bioscience
CEO
David J. Lennon
Headquarters Pacific Palisades, ca
USA
Website
Sector
Materials
Industry
Chemicals
IPO
16/02/2018
Employees 53

Ticker symbols

Exchange Symbol
NASDAQ
AADI
Frankfurt
3350.F
Düsseldorf
3350.DU
München
3350.MU
NASDAQ
WHWK
🍪

Parqet  uses cookies. Learn more